🔗 Share this article Patients Discontinuing Anti-Obesity Injections Regain Weight at a Quadrupled Rate Than People Using Diet and Exercise Weight management often requires long-term strategies. A recent study reveals that patients who stop using popular GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds at a significantly accelerated pace than those who stop traditional lifestyle regimens. Published data in a leading health publication shows that while obese individuals frequently drop about a fifth of their total mass while using the jabs, the mass comes back at an average rate of 0.8 kg per month after stopping. "Individuals buying these treatments need to be cognizant of the danger of rapid rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb. That rate of regain implies a reversion to pre-treatment weight in about 18 months. Comparing Treatments The study, which looked at dozens of studies involving over 9,000 of participants, compared the effects of these new drugs with other pills. The team note that individuals who lose weight through lifestyle changes alone typically see a slower creep back—approximately 0.1 kg a month—after stopping. Understanding the Rapid Regain Doctors propose the way of the injections accounts for the amplified rebound. These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate hunger. "Artificially providing the hormone levels far above than normal might result in the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher. "Discontinuation of this medication leads to hunger is uncontrolled, making binge eating a significant risk." An Ongoing Condition? Medical guidelines recommend the injections for people with weight-linked health risks, alongside recommended lifestyle changes. Many experts say that, due to the significant potential of weight regain, the treatment should be considered long-term. This opinion is supported by drug manufacturers, who state that the findings "emphasize the long-term character of excess weight," similar to managing conditions like high blood pressure. User Testimonies People who have come off the jabs describe a intense resurgence of appetite. "I experienced something flipping and you become starving," recalled an individual. This challenge is worsened if individuals have not established permanent dietary or behavioural modifications during therapy. Significant Adoption Survey data suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow. Use is higher among females compared to men. The middle-aged demographic shows the highest usage rates. Many obtain the drugs through private prescriptions rather than public health services. Ultimately, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone cure and lasting health benefits likely depends on ongoing behavioural management.
Weight management often requires long-term strategies. A recent study reveals that patients who stop using popular GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds at a significantly accelerated pace than those who stop traditional lifestyle regimens. Published data in a leading health publication shows that while obese individuals frequently drop about a fifth of their total mass while using the jabs, the mass comes back at an average rate of 0.8 kg per month after stopping. "Individuals buying these treatments need to be cognizant of the danger of rapid rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb. That rate of regain implies a reversion to pre-treatment weight in about 18 months. Comparing Treatments The study, which looked at dozens of studies involving over 9,000 of participants, compared the effects of these new drugs with other pills. The team note that individuals who lose weight through lifestyle changes alone typically see a slower creep back—approximately 0.1 kg a month—after stopping. Understanding the Rapid Regain Doctors propose the way of the injections accounts for the amplified rebound. These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate hunger. "Artificially providing the hormone levels far above than normal might result in the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher. "Discontinuation of this medication leads to hunger is uncontrolled, making binge eating a significant risk." An Ongoing Condition? Medical guidelines recommend the injections for people with weight-linked health risks, alongside recommended lifestyle changes. Many experts say that, due to the significant potential of weight regain, the treatment should be considered long-term. This opinion is supported by drug manufacturers, who state that the findings "emphasize the long-term character of excess weight," similar to managing conditions like high blood pressure. User Testimonies People who have come off the jabs describe a intense resurgence of appetite. "I experienced something flipping and you become starving," recalled an individual. This challenge is worsened if individuals have not established permanent dietary or behavioural modifications during therapy. Significant Adoption Survey data suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow. Use is higher among females compared to men. The middle-aged demographic shows the highest usage rates. Many obtain the drugs through private prescriptions rather than public health services. Ultimately, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone cure and lasting health benefits likely depends on ongoing behavioural management.